| Schedule of net revenues by product |
The following tables detail AbbVie's worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2024 | | 2023 | | 2022 | | Immunology | | | | | | | Humira | United States | $ | 7,142 | | | $ | 12,160 | | | $ | 18,619 | | | International | 1,851 | | | 2,244 | | | 2,618 | | | Total | $ | 8,993 | | | $ | 14,404 | | | $ | 21,237 | | | Skyrizi | United States | $ | 10,086 | | | $ | 6,753 | | | $ | 4,484 | | | International | 1,632 | | | 1,010 | | | 681 | | | Total | $ | 11,718 | | | $ | 7,763 | | | $ | 5,165 | | | Rinvoq | United States | $ | 4,259 | | | $ | 2,824 | | | $ | 1,794 | | | International | 1,712 | | | 1,145 | | | 728 | | | Total | $ | 5,971 | | | $ | 3,969 | | | $ | 2,522 | | | Oncology | | | | | | | Imbruvica | United States | $ | 2,448 | | | $ | 2,665 | | | $ | 3,426 | | | Collaboration revenues | 899 | | | 931 | | | 1,142 | | | Total | $ | 3,347 | | | $ | 3,596 | | | $ | 4,568 | | | Venclexta | United States | $ | 1,234 | | | $ | 1,087 | | | $ | 1,009 | | | International | 1,349 | | | 1,201 | | | 1,000 | | | Total | $ | 2,583 | | | $ | 2,288 | | | $ | 2,009 | | Elahere(a) | United States | $ | 477 | | | $ | — | | | $ | — | | | International | 2 | | | — | | | — | | | Total | $ | 479 | | | $ | — | | | $ | — | | | Epkinly | Collaboration revenues | $ | 118 | | | $ | 28 | | | $ | — | | | International | 28 | | | 3 | | | — | | | Total | $ | 146 | | | $ | 31 | | | $ | — | | | Aesthetics | | | | | | Botox Cosmetic | United States | $ | 1,682 | | | $ | 1,670 | | | $ | 1,654 | | | International | 1,038 | | | 1,012 | | | 961 | | | Total | $ | 2,720 | | | $ | 2,682 | | | $ | 2,615 | | Juvederm Collection | United States | $ | 469 | | | $ | 519 | | | $ | 548 | | | International | 708 | | | 859 | | | 880 | | | Total | $ | 1,177 | | | $ | 1,378 | | | $ | 1,428 | | Other Aesthetics | United States | $ | 1,118 | | | $ | 1,060 | | | $ | 1,122 | | | International | 161 | | | 174 | | | 168 | | | Total | $ | 1,279 | | | $ | 1,234 | | | $ | 1,290 | | | Neuroscience | | | | | | Botox Therapeutic | United States | $ | 2,718 | | | $ | 2,476 | | | $ | 2,255 | | | International | 565 | | | 515 | | | 464 | | | Total | $ | 3,283 | | | $ | 2,991 | | | $ | 2,719 | | Vraylar | United States | $ | 3,260 | | | $ | 2,755 | | | $ | 2,037 | | | International | 7 | | | 4 | | | 1 | | | Total | $ | 3,267 | | | $ | 2,759 | | | $ | 2,038 | | | Duodopa | United States | $ | 96 | | | $ | 97 | | | $ | 95 | | | International | 351 | | | 371 | | | 363 | | | Total | $ | 447 | | | $ | 468 | | | $ | 458 | | Ubrelvy | United States | $ | 981 | | | $ | 803 | | | $ | 680 | | | International | 25 | | | 12 | | | — | | | Total | $ | 1,006 | | | $ | 815 | | | $ | 680 | | | Qulipta | United States | $ | 628 | | | $ | 405 | | | $ | 158 | | | International | 30 | | | 3 | | | — | | | Total | $ | 658 | | | $ | 408 | | | $ | 158 | |
| | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2024 | | 2023 | | 2022 | Other Neuroscience | United States | $ | 224 | | | $ | 254 | | | $ | 456 | | | International | 114 | | | 22 | | | 19 | | | Total | $ | 338 | | | $ | 276 | | | $ | 475 | | | Eye Care | | | | | | | Ozurdex | United States | $ | 138 | | | $ | 143 | | | $ | 139 | | | International | 356 | | | 329 | | | 289 | | | Total | $ | 494 | | | $ | 472 | | | $ | 428 | | Lumigan/Ganfort | United States | $ | 187 | | | $ | 173 | | | $ | 242 | | | International | 242 | | | 259 | | | 272 | | | Total | $ | 429 | | | $ | 432 | | | $ | 514 | | Alphagan/Combigan | United States | $ | 95 | | | $ | 121 | | | $ | 202 | | | International | 153 | | | 151 | | | 144 | | | Total | $ | 248 | | | $ | 272 | | | $ | 346 | | Restasis | United States | $ | 172 | | | $ | 382 | | | $ | 621 | | | International | 52 | | | 54 | | | 45 | | | Total | $ | 224 | | | $ | 436 | | | $ | 666 | | Other Eye Care | United States | $ | 472 | | | $ | 433 | | | $ | 399 | | | International | 375 | | | 370 | | | 348 | | | Total | $ | 847 | | | $ | 803 | | | $ | 747 | | | Other Key Products | | | | | | | Mavyret | United States | $ | 595 | | | $ | 659 | | | $ | 755 | | | International | 716 | | | 771 | | | 786 | | | Total | $ | 1,311 | | | $ | 1,430 | | | $ | 1,541 | | | Creon | United States | $ | 1,383 | | | $ | 1,268 | | | $ | 1,278 | | Linzess/Constella | United States | $ | 916 | | | $ | 1,073 | | | $ | 1,003 | | | International | 38 | | | 35 | | | 32 | | | Total | $ | 954 | | | $ | 1,108 | | | $ | 1,035 | | | All other | | $ | 3,032 | | | $ | 3,035 | | | $ | 4,137 | | | Total net revenues | | $ | 56,334 | | | $ | 54,318 | | | $ | 58,054 | |
(a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.
|
| Schedule of net revenues to external customers by geographic area |
Net revenues to external customers by geographic area, based on product shipment destination, were as follows: | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2024 | | 2023 | | 2022 | | United States | $ | 43,029 | | | $ | 41,883 | | | $ | 45,713 | | | Germany | 1,465 | | | 1,266 | | | 1,340 | | | Japan | 1,122 | | | 1,008 | | | 956 | | | Canada | 1,088 | | | 1,076 | | | 1,159 | | | China | 917 | | | 950 | | | 912 | | | France | 776 | | | 780 | | | 787 | | | Spain | 528 | | | 501 | | | 506 | | | United Kingdom | 522 | | | 417 | | | 462 | | | Italy | 511 | | | 484 | | | 444 | | | Brazil | 464 | | | 439 | | | 430 | | | Australia | 463 | | | 472 | | | 508 | | | All other countries | 5,449 | | | 5,042 | | | 4,837 | | | Total net revenues | $ | 56,334 | | | $ | 54,318 | | | $ | 58,054 | |
|